Immunomodulatory therapies readily focus on the interactions between PD-L1 on tumor cells and its receptor PD-1 on T cells because the binding of PD-1 to the PD-L1 breaks the activation of T cell anti-tumor function. Here, CD274 is linked to neoplasm.